DSS Prices Public Offering Expected to Raise $1M
DSS announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $1M, before deducting underwriting fees and other offering expenses payable by the Company. The offering consists of 900,000 shares of common stock. The public offering price per share of common stock is $1.00. In addition, the Company has granted the underwriter an overallotment option to purchase up to an additional 135,000 shares of common stock, representing 15% of the number of shares offered, which option is exercisable in whole or in part at any time up to 45 days after the date of this prospectus. Aggregate gross proceeds to the Company are expected to be approximately $900,000, or $1.035M if the over-allotment option is exercised in full. The transaction is expected to close on or about February 5, 2026, subject to the satisfaction of customary closing conditions. Aegis Capital Corp. is acting as the sole book-running manager for the offering.
Trade with 70% Backtested Accuracy
Analyst Views on DSS
About DSS
About the author

- Withdrawal of Registration: DSS, Inc. announced the withdrawal of its previously filed S-1 registration statement, as management concluded that current market conditions and deal terms do not reflect the value the company aims to create for shareholders, leading to the decision to pause the financing plan.
- Capital Market Strategy: The company stated it will continue to evaluate financing alternatives and capital market opportunities to ensure capital access at the most favorable time and terms, supporting its strategic plan and business value.
- Stable Business Outlook: Despite the withdrawal, DSS maintains confidence in its business outlook, operating strategy, and asset value, with CEO Jason Grady emphasizing the focus on executing the business plan and creating long-term shareholder value.
- Strategic Merger Progress: DSS continues to advance its merger plan with Impact Biomedical, believing that this transaction has the potential to create significant long-term value for shareholders, demonstrating the company's strategic flexibility across its diversified business lines.
- Audit Opinion Disclosure: DSS, Inc. received an audit opinion from HTL International LLC in its 2025 fiscal year report, which includes a 'going concern' qualification, indicating potential financial uncertainties that could impact investor confidence and stock performance.
- Compliance Announcement Requirement: Under NYSE American LLC Company Guide Section 610(b), DSS is required to publicly disclose this audit opinion, although the announcement does not amend the financial statements or annual report for the fiscal year 2025, demonstrating the company's commitment to transparency in compliance.
- Diversified Business Model: DSS operates as a multinational company across various sectors including product packaging, biotechnology, commercial lending, and securities investment management, aiming to unlock value through the development of high-growth subsidiaries and strategic IPOs, despite current audit challenges.
- Forward-Looking Statement Risks: The company notes that forward-looking statements may be subject to various risks and uncertainties, which could lead to actual results differing significantly from expectations, potentially further affecting investor confidence in the company's future prospects.

Loan and Securities Details: A company has secured a loan of $2.45 million for convertible notes and warrants, which will halt the purchase of 16,554,055 shares.
Regulatory Filing: The information regarding the loan and share purchase has been disclosed in a SEC filing.

- Company Announcement: A company named ALSENT INC has entered into a securities purchase agreement with DSS, Inc.
- Date of Agreement: The agreement was finalized on March 26, 2026, indicating a future transaction.







